Higher readmission rates after PCI versus CABG for left main coronary artery disease: EXCEL trial
USA: Findings from a 5-year follow-up of the EXCEL trial revealed that surgery has the upper hand over angioplasty for revascularization for left main coronary disease concerning hospital readmission rates.
The study was published online in the Journal of the American College of Cardiology.
In the EXCEL trial, readmission during 5-year follow-up after revascularization for left main coronary artery disease (LMCAD) was common and more frequent after percutaneous coronary intervention (PCI) than coronary artery bypass grafting (CABG). Readmissions were tied to an increased risk of all-cause death, more so after PCI than with CABG.
"This thought-provoking analysis highlights the risks and implications of late readmissions after revascularization for unprotected left main coronary artery disease," Wayne B. Batchelor and Abdulla A. Damluji from Inova Schar Heart and Vascular in Falls Church, Virginia, wrote in an accompanying editorial.
The frequency of and the relationship between hospital readmissions and outcomes following revascularization for left main coronary artery disease are unknown. Ioanna Kosmidou, from Cardiovascular Research Foundation in New York, New York, USA, and colleagues aimed to study the predictors, incidence, and clinical impact of readmissions following PCI and coronary artery bypass grafting for LMCAD.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.